整合素阻断剂抗肿瘤药物研究进展

Development of integrin inhibitors in antitumor therapy

整合素是存在于细胞表面的跨膜糖蛋白受体,能介导细胞间的黏附,参与血管生成和肿瘤转移,与肿瘤的发生发展密切相关。以整合素为靶点进行抗肿瘤治疗,可有效抑制肿瘤的生长和转移。本文主要从抗肿瘤生长类药物、抗肿瘤转移类药物、抗血管生成类药物等方面对近年来整合素阻断剂抗肿瘤药物研究进展进行综述,并对整合素靶向给药的剂量问题进行了讨论。

Integrins are transmembrane glycoprotein receptor on cell surface, which can mediate adhesion between cells and involve in angiogenesis and tumor metastasis. Therefore, integrins are closely related with tumorigenesis and tumor development. Integrin-targeted anti-tumor therapy could effectively inhibit tumor growth and metastasis. This review mainly focused on development of integrin inhibitors in antitumor therapy in recent years from aspects of anti-tunor growth, anti- tumor metastasis, anti-angiogenesis and so on. Further more, dual function of doses in integrin-targeted therapy are also discussed.